Lupus & antiphospholipid syndrome
Antimitochondrial antibodies in systemic lupus erythematosus are associated with and predict nephritis, arterial vascular events, and mortality
Authors' conclusion
Baseline and most recent assessments of AMA levels may help identify individuals at higher risk of severe outcomes in SLE, including mortality.
Study context
- Population
- Participants of the Systemic Lupus International Collaborating Clinics inception cohort with systemic lupus erythematosus (SLE)
- Participants
- 1,114 participants
- Exposure
- Higher vs lower antimitochondrial antibodies (AMA) levels
- Outcome
- Nephritis, arterial vascular events (AVE) and other outcomes including mortality
Methodological detailsmultivariable Cox proportional hazards regression, adjusted for biological sex, age, medications and other clinical factors
- Multivariable Cox proportional hazards regression
- Adjusted for biological sex, age, medications and other clinical factors
Main finding
As reported in the abstract
Nephritis
Most recent antimitochondrial DNA (AmtDNA), aHR per 1 SD increase
1.61
95% CI 1.43–1.82
Most recent antimitochondrial RNA (AmtRNA), aHR per 1 SD increase (1.46-1.73)
1.59
Observational data: associations, not effects.
Further findings
Early mortality
- Higher baseline antiwhole mitochondria (AwMA), aHR (1.02-1.40)
- 1.19
Mortality throughout follow-up
- Most recent AmtDNA, aHR (1.28-2.19)
- 1.68
Arterial vascular events (AVE)
- Impact of higher AmtRNA stronger in females
AMA titres, SLE vs healthy individuals
- All AMA titres elevated in SLE vs healthy individuals
Original publication
Antimitochondrial antibodies in systemic lupus erythematosus are associated with and predict nephritis, arterial vascular events, and mortality. Ann Rheum Dis. Published 13 December 2025. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →